- Home
- IDR vs SLN Comparison
IDR vs SLN Comparison
Compare IDR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- SLN
- Stock Information
- Founded
- IDR 1996
- SLN 1994
- Country
- IDR United States
- SLN United Kingdom
- Employees
- IDR N/A
- SLN N/A
- Industry
- IDR Precious Metals
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- SLN Health Care
- Exchange
- IDR Nasdaq
- SLN Nasdaq
- Market Cap
- IDR 154.1M
- SLN 165.3M
- IPO Year
- IDR N/A
- SLN N/A
- Fundamental
- Price
- IDR $13.76
- SLN $5.84
- Analyst Decision
- IDR Strong Buy
- SLN Buy
- Analyst Count
- IDR 1
- SLN 5
- Target Price
- IDR $17.50
- SLN $32.60
- AVG Volume (30 Days)
- IDR 315.9K
- SLN 119.0K
- Earning Date
- IDR 07-29-2025
- SLN 08-14-2025
- Dividend Yield
- IDR N/A
- SLN N/A
- EPS Growth
- IDR 144.40
- SLN N/A
- EPS
- IDR 0.62
- SLN N/A
- Revenue
- IDR $27,144,971.00
- SLN $27,701,000.00
- Revenue This Year
- IDR $9.76
- SLN N/A
- Revenue Next Year
- IDR N/A
- SLN N/A
- P/E Ratio
- IDR $22.27
- SLN N/A
- Revenue Growth
- IDR 67.42
- SLN N/A
- 52 Week Low
- IDR $8.90
- SLN $1.97
- 52 Week High
- IDR $19.75
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- IDR 48.18
- SLN 58.14
- Support Level
- IDR $14.00
- SLN $5.06
- Resistance Level
- IDR $14.79
- SLN $5.85
- Average True Range (ATR)
- IDR 0.62
- SLN 0.51
- MACD
- IDR 0.13
- SLN -0.06
- Stochastic Oscillator
- IDR 43.72
- SLN 37.41
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.